跳至主要内容
临床试验/IRCT20200610047722N1
IRCT20200610047722N1已完成早期 1 期

Comparing the efficacy of Allicin derivatives capsule and Placebo as an adjuvant for patients with COVID-19: A double-blind randomized placebo controlled clinical trial

Hossein Nik Tale0 个研究点目标入组 25 人开始时间: 待定最近更新:
适应症

试验速览

阶段
早期 1 期
状态
已完成
发起方
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 70 years(—)
性别
All

入选标准

  • Patients with RT-PCR positive for SARS-CoV-2 , clinical sign and symptoms (fever, cough and myalgia) and CT scan indicate COVID-19 positive.
  • Sign consent form

排除标准

  • History of allergic reaction to Allicin
  • History of allergic reaction to Garlic or Onion
  • History of low blood pressure or gastrointestinal tract bleeding
  • Low blood pressure and the beginning of study (lower that 120/80 mmHg)
  • Patients with immune deficiency disorders (patients undergo chemotherapy, organ or bone marrow transplants and patients with autoimmune disease)
  • No need to use ventilator during the study
  • Unable to swallow the oral medication
  • Breastfeeding

研究者

发起方
Hossein Nik Tale

相似试验